Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6–11 Years: Actual Observations and Clinical Perspectives.
Loading...
Identifiers
Publication date
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
Cystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life studies.
This study aimed to assess the impact of ETI on aerobic capacity in children with CF aged 6–11 years under real-life conditions and to evaluate whether prior CFTR modulator treatment affects these outcomes.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Pérez-Ruiz, M., Te Bos, M., Fernández-García, P., Manuel, C. D., Morales-Tirado, A., López-Neyra, A., Valbuena, M. R. D., Rubio, M., & Sanz-Santiago, V. (2025). Evaluation of the impact of elexacaftor/tezacaftor/ivacaftor on aerobic capacity in children with cystic fibrosis aged 6–11 years: Actual observations and clinical perspectives. Archivos de Bronconeumología, S0300289625000717. https://doi.org/10.1016/j.arbres.2025.02.010